A5064274146- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Lipids, and Metabolism
- Pediatric Hepatobiliary Diseases and Treatments
- Gastric Cancer Management and Outcomes
- Drug Transport and Resistance Mechanisms
- Cancer Mechanisms and Therapy
- Gut microbiota and health
- Renal cell carcinoma treatment
- Hepatitis B Virus Studies
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Galectins and Cancer Biology
- Hepatitis C virus research
- Esophageal Cancer Research and Treatment
- IL-33, ST2, and ILC Pathways
- Liver Disease and Transplantation
- Alcohol Consumption and Health Effects
- Lung Cancer Treatments and Mutations
- Cancer-related molecular mechanisms research
- Clostridium difficile and Clostridium perfringens research
- Lipid metabolism and disorders
- Multiple and Secondary Primary Cancers
- Nutrition and Health in Aging
- Diet and metabolism studies
Nagoya University
2019-2025
Fujita Health University Hospital
2023-2024
Fujita Health University Bantane Hospital
2023-2024
Fujita Health University
2023-2024
Kinan Hospital
2016
The combination of atezolizumab plus bevacizumab (Atz/Bev) has become widely used as a first-line therapy for advanced hepatocellular carcinoma (HCC). However, post-Atz/Bev therapy, evidence on the outcomes molecular targeted agents, such lenvatinib, is limited. present study aimed to assess clinical effectiveness lenvatinib HCC in patients who had previously undergone Atz/Bev treatment.Twenty with HCC, received after treatment, were enrolled study. In particular, we examined impact adverse...
The relationship between antitumor response and tumor marker changes was evaluated in patients with advanced hepatocellular carcinoma treated durvalumab plus tremelimumab (Dur/Tre). Forty were enrolled this retrospective evaluation of treatment outcomes. According to the Response Evaluation Criteria for Solid Tumors version 1.1 at 8 weeks, objective (OR) rate 25% disease control (DC) 57.5%. median alpha-fetoprotein (AFP) ratio 4 weeks 0.39 who achieved OR (8W-OR group), significantly lower...
The impact of a high-fat diet (HFD) on intestinal permeability has been well established. When bacteria and their metabolites from the tract flow into portal vein, inflammation in liver is triggered. However, exact mechanism behind development leaky gut caused by an HFD unclear. In this study, we investigated underlying related to HFD. C57BL/6J mice were fed or control for 24 weeks, small intestine epithelial cells (IECs) analyzed using deep quantitative proteomics. A significant increase...
Abstract Non-alcoholic steatohepatitis (NASH) occurrence has been increasing and is becoming a major cause of liver cirrhosis cancer. However, effective treatments for NASH are still lacking. We examined the benefits serum-free conditioned medium from stem cells derived human exfoliated deciduous teeth (SHED-CM) on murine non-alcoholic model induced by combination Western diet (WD) repeated administration low doses carbon tetrachloride intraperitoneally, focusing gut-liver axis. showed that...
Abstract Background Antitumor necrosis factor (TNF)-α antibodies have improved the outcome of inflammatory bowel disease (IBD); but half patients remain unresponsive to treatment. Interleukin-18 (IL-18) gene polymorphism is associated with resistance anti-TNF-α antibodies, therapies targeting IL-18 not been clinically applied. Only mature protein biologically active, and we aimed investigate whether specific inhibition using a monoclonal antibody (mAb) against neoepitope caspase-cleaved...
This study investigates novel short-lived long noncoding RNAs (lncRNAs) in mice with altered expression metabolic dysfunction-associated steatotic liver (MASH) and fibrosis. LncRNAs share similarities mRNAs their transcription by RNA polymerase II, possession of a 5' cap structure, presence polyA tail. We identified two lncRNAs, Kcnq1ot1 Rmst, significantly decreased both conditions. These lncRNAs showed dramatic changes MASH livers induced Western diets CCl
We present the first reported case of pseudocirrhosis arising after a dramatic response to chemotherapy in metastatic gastric cancer. A 74-year-old man was diagnosed with adenocarcinoma having multiple liver metastases. His general condition poor, an Eastern Cooperative Oncology Group performance status 3, inadequate oral intake, and jaundice (total bilirubin 2.8 mg/dl). Chemotherapy oxaliplatin, l-leucovorin, 5-fluorouracil (modified FOLFOX-6) initiated. After four treatment cycles, he...
Biliary atresia (BA) is a congestive biliary disease that develops in the neonatal period or early infancy. It may present with portal hypertension and varices needing treatment (VNT) even after successful Kasai portoenterostomy. This study aimed to stratify risk of VNT children adolescents BA.
The relationship between antitumor response and tumor marker changes was evaluated in patients with advanced hepatocellular carcinoma treated durvalumab plus tremelimumab (Dur/Tre). Thirty-two were enrolled this retrospective evaluation of treatment outcomes. According to Response Evaluation Criteria for Solid Tumors at 8 weeks, the objective rate (OR) 25% disease control (DC) 56.3%. Median alpha-fetoprotein (AFP) ratio 4 weeks 0.310 who achieved OR (8W-OR group), significantly lower than...
To investigate the characteristics and prognosis of patients with advanced hepatocellular carcinoma (HCC) treated atezolizumab bevacizumab (Atz/Bev) who achieved a complete response (CR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST).
Abstract Real-world clinical cases of molecularly targeted agent (MTA) administration to patients with advanced hepatocellular carcinoma (HCC) ≥50% liver occupation have been reported, but treatment outcomes rarely described. We encountered several in which albumin–bilirubin (ALBI) scores deteriorated markedly and C-reactive protein (CRP) levels elevated the early post-dose period. The present study therefore investigated changes ALBI score CRP after initiating MTA HCC occupation, focusing...
Abstract Background Elevated bile acid levels have been associated with liver tumors in fatty liver. Ileal transporter inhibitors may inhibit absorption the distal ileum and increase colon, potentially decreasing serum hepatic acids. This study investigated impact of these factors on tumors. Methods C57BL/6J mice received a one-time intraperitoneal injection 25 mg/kg diethylnitrosamine. They were fed choline-deficient high-fat diet for 20 weeks starting from 8 age, or without elobixibat (EA...